Recombinant Human IL-17B Protein

R&D Systems, part of Bio-Techne | Catalog # 1248-IB

Catalog #
Availability
Size / Price
Qty
Carrier Free
1248-IB-025/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
1248-IB-025
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems E. coli-derived Recombinant Human IL-17B Protein (1248-IB)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

E. coli

Accession #

Q9UHF5

Conjugate

Unconjugated

Applications

Bioactivity

View all IL-17B Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human IL-17B protein
Gln21-Phe180, with an N-terminal Met

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

18.3 kDa

Activity

Measured by its ability to induce IL-8 secretion by HepG2 human hepatocellular carcinoma cells. Tang, Y. et al. (2011) Clin. Exp. Immunol. 166:281.
The ED50 for this effect is 0.4-2 μg/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 1248-IB
Formulation Lyophilized from a 0.2 μm filtered solution in NaH2PO4 and NaCl with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 1248-IB/CF
Formulation Lyophilized from a 0.2 μm filtered solution in NaH2PO4 and NaCl.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-17B

Interleukin-17B (IL-17B), is an approximately 20 kDa glycosylated cytokine that plays a role in inflammation and bone growth. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature human IL-17B shares 90% and 91% amino acid sequence identity with mouse and rat IL-17B, respectively (3, 4). IL-17B binds to IL-17 RB and induces the production of inflammatory cytokines and the infiltration of inflammatory immune cells (3, 4). IL-17B is expressed in the central nervous system, testis, ovary, stomach, pancreas, and small intestine (3-5). In the skeletal system, IL-17B is expressed in bone collars surrounding primary ossification centers as well as in epiphyseal plate chondrocytes during development and after bone fracture (6, 7). IL-17B is up-regulated in arthritic cartilage where it exacerbates the severity of disease (8). It is also up-regulated in aggressive breast cancer cell lines, and its exaggerated signaling through IL-17RB promotes tumorigenicity (9). It inhibits the adhesion of vascular endothelial cells to Matrigel and enhances their migration (10).

References

  1. Gaffen, S.L. (2009) Nat. Rev. Immunol. 9:556.
  2. Cua, D.J. and C.M. Tato (2010) Nat. Rev. Immunol. 10:479.
  3. Shi, Y. et al. (2000) J. Biol. Chem. 275:19167.
  4. Li, H. et al. (2000) Proc. Natl. Acad. Sci. USA 97:773.
  5. Moore, E.E. et al. (2002) Neuromuscul. Disord. 12:141.
  6. Kokubu, T. et al. (2008) J. Histochem. Cytochem. 56:89.
  7. You, Z. et al. (2005) Biochem. Biophys. Res. Commun. 326:624.
  8. Yamaguchi, Y. et al. (2007) J. Immunol. 179:7128.
  9. Huang, C.-K. et al. (2013) Oncogene July 15 Epub.
  10. Sanders, A.J. et al. (2010) J. Oncol. 2010:817375.

Long Name

Interleukin 17B

Alternate Names

IL17B

Entrez Gene IDs

27190 (Human); 56069 (Mouse)

Gene Symbol

IL17B

UniProt

Q9UHF5

Additional IL-17B Products

Product Documents for Recombinant Human IL-17B Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 1248-IB (with carrier)
Download SDS 1248-IB/CF (carrier free)

Product Specific Notices for Recombinant Human IL-17B Protein

For research use only

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.